176 related articles for article (PubMed ID: 35119623)
1. I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response.
Plyku D; Hobbs RF; Wu D; Garcia C; Sgouros G; Van Nostrand D
Ann Nucl Med; 2022 Mar; 36(3):213-223. PubMed ID: 35119623
[TBL] [Abstract][Full Text] [Related]
2. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
Wierts R; Brans B; Havekes B; Kemerink GJ; Halders SG; Schaper NN; Backes WH; Mottaghy FM; Jentzen W
J Nucl Med; 2016 Jul; 57(7):1027-32. PubMed ID: 26917706
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
[TBL] [Abstract][Full Text] [Related]
4. Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.
Hobbs RF; Jentzen W; Bockisch A; Sgouros G
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):79-91. PubMed ID: 23474639
[TBL] [Abstract][Full Text] [Related]
5. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
[TBL] [Abstract][Full Text] [Related]
6. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging.
Jentzen W; Hoppenbrouwers J; van Leeuwen P; van der Velden D; van de Kolk R; Poeppel TD; Nagarajah J; Brandau W; Bockisch A; Rosenbaum-Krumme S
J Nucl Med; 2014 Nov; 55(11):1759-65. PubMed ID: 25332440
[TBL] [Abstract][Full Text] [Related]
7. 3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART) combined with external beam radiation therapy.
Ferrari ME; Cremonesi M; Di Dia A; Botta F; De Cicco C; Sarnelli A; Pedicini P; Calabrese M; Orecchia R; Pedroli G; Paganelli G
Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1702-11. PubMed ID: 22890802
[TBL] [Abstract][Full Text] [Related]
8. The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients.
Mauguen A; Grewal RK; Augensen F; Abusamra M; Mahajan S; Jayaprakasam VS; Osborne J; Haque S; Wong BZY; Ghossein RA; Fagin J; Schӧder H; Tuttle RM; Ho A; Humm JL; Larson SM
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2971-2983. PubMed ID: 37171634
[TBL] [Abstract][Full Text] [Related]
9. Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?
Sun F; Gerrard GE; Roberts JK; Telford T; Namini S; Waller M; Flux G; Gill VM
Clin Oncol (R Coll Radiol); 2017 May; 29(5):310-315. PubMed ID: 28132755
[TBL] [Abstract][Full Text] [Related]
10. Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer.
Abuqbeitah M; Demir M; Kabasakal L; Çavdar İ; Uslu-Beşli L; Yeyin N; Razavikhosroshahi S; Sönmezoğlu K
Nucl Med Commun; 2018 Nov; 39(11):969-975. PubMed ID: 30180046
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck.
Nagarajah J; Jentzen W; Hartung V; Rosenbaum-Krumme S; Mikat C; Heusner TA; Antoch G; Bockisch A; Stahl A
Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1862-8. PubMed ID: 21739331
[TBL] [Abstract][Full Text] [Related]
12. 124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer.
Jentzen W; Verschure F; van Zon A; van de Kolk R; Wierts R; Schmitz J; Bockisch A; Binse I
J Nucl Med; 2016 Oct; 57(10):1499-1504. PubMed ID: 27199362
[TBL] [Abstract][Full Text] [Related]
13. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
14. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
Sgouros G; Kolbert KS; Sheikh A; Pentlow KS; Mun EF; Barth A; Robbins RJ; Larson SM
J Nucl Med; 2004 Aug; 45(8):1366-72. PubMed ID: 15299063
[TBL] [Abstract][Full Text] [Related]
15. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Hobbs RF; Stahl A; Knust J; Sgouros G; Bockisch A
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):884-95. PubMed ID: 20069293
[TBL] [Abstract][Full Text] [Related]
16. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
Med Phys; 2016 Oct; 43(10):5279. PubMed ID: 27782699
[TBL] [Abstract][Full Text] [Related]
17. Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
Rani D; Kaisar S; Awasare S; Kamaldeep ; Abhyankar A; Basu S
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1767-80. PubMed ID: 24687139
[TBL] [Abstract][Full Text] [Related]
18. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer.
Freudenberg LS; Jentzen W; Marlowe RJ; Koska WW; Luster M; Bockisch A
Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):690-3. PubMed ID: 18058605
[TBL] [Abstract][Full Text] [Related]
19. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
[TBL] [Abstract][Full Text] [Related]
20. Theranostic Surrogacy of [
Kim SB; Lee MS; Song IH; Park HS; Kim SE
Mol Pharm; 2023 Jul; 20(7):3460-3470. PubMed ID: 37294909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
